These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 33302791)
1. Brexanolone: A Novel Drug for the Treatment of Postpartum Depression. Patatanian E; Nguyen DR J Pharm Pract; 2022 Jun; 35(3):431-436. PubMed ID: 33302791 [TBL] [Abstract][Full Text] [Related]
2. Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations. Leader LD; O'Connell M; VandenBerg A Pharmacotherapy; 2019 Nov; 39(11):1105-1112. PubMed ID: 31514247 [TBL] [Abstract][Full Text] [Related]
3. Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression. Powell JG; Garland S; Preston K; Piszczatoski C Ann Pharmacother; 2020 Feb; 54(2):157-163. PubMed ID: 31476884 [No Abstract] [Full Text] [Related]
4. Brexanolone for postpartum depression. Hutcherson TC; Cieri-Hutcherson NE; Gosciak MF Am J Health Syst Pharm; 2020 Feb; 77(5):336-345. PubMed ID: 32073124 [TBL] [Abstract][Full Text] [Related]
5. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders. Walkery A; Leader LD; Cooke E; VandenBerg A Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503 [TBL] [Abstract][Full Text] [Related]
6. Brexanolone (Zulresso) for postpartum depression. Med Lett Drugs Ther; 2019 May; 61(1571):68-70. PubMed ID: 31169804 [No Abstract] [Full Text] [Related]
7. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Meltzer-Brody S; Colquhoun H; Riesenberg R; Epperson CN; Deligiannidis KM; Rubinow DR; Li H; Sankoh AJ; Clemson C; Schacterle A; Jonas J; Kanes S Lancet; 2018 Sep; 392(10152):1058-1070. PubMed ID: 30177236 [TBL] [Abstract][Full Text] [Related]
8. Evaluating brexanolone for the treatment of postpartum depression. Payne JL Expert Opin Pharmacother; 2021 Jun; 22(8):959-964. PubMed ID: 33645386 [TBL] [Abstract][Full Text] [Related]
9. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Kanes SJ; Colquhoun H; Doherty J; Raines S; Hoffmann E; Rubinow DR; Meltzer-Brody S Hum Psychopharmacol; 2017 Mar; 32(2):. PubMed ID: 28370307 [TBL] [Abstract][Full Text] [Related]
10. Brexanolone for the treatment of patients with postpartum depression. Morrison KE; Cole AB; Thompson SM; Bale TL Drugs Today (Barc); 2019 Sep; 55(9):537-544. PubMed ID: 31584571 [TBL] [Abstract][Full Text] [Related]
12. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Kanes S; Colquhoun H; Gunduz-Bruce H; Raines S; Arnold R; Schacterle A; Doherty J; Epperson CN; Deligiannidis KM; Riesenberg R; Hoffmann E; Rubinow D; Jonas J; Paul S; Meltzer-Brody S Lancet; 2017 Jul; 390(10093):480-489. PubMed ID: 28619476 [TBL] [Abstract][Full Text] [Related]
13. Brexanolone For Postpartum Depression: A Novel Approach and a Call for Comprehensive Postpartum Care. Jarman AF; MacLean JV; Barron RJ; Wightman RS; McGregor AJ Clin Ther; 2020 Jan; 42(1):231-235. PubMed ID: 31910998 [TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development. Frieder A; Fersh M; Hainline R; Deligiannidis KM CNS Drugs; 2019 Mar; 33(3):265-282. PubMed ID: 30790145 [TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy. Reddy DS; Mbilinyi RH; Estes E Psychopharmacology (Berl); 2023 Sep; 240(9):1841-1863. PubMed ID: 37566239 [TBL] [Abstract][Full Text] [Related]
16. Brexanolone: First Global Approval. Scott LJ Drugs; 2019 May; 79(7):779-783. PubMed ID: 31006078 [TBL] [Abstract][Full Text] [Related]
17. Brexanolone Is the First Drug Specifically for Postpartum Depression. Fantasia HC Nurs Womens Health; 2019 Oct; 23(5):450-454. PubMed ID: 31445988 [TBL] [Abstract][Full Text] [Related]